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The growing presence of cardiovascular dis-
eases coexisting with other diseases in the popula-
tion, and the increasing number of deaths associated
with it causes that so-called fixed-dose combination
(FDC) preparations are being developed to be used
in polytherapy.
In recent years, a number of studies have been
conducted to assess the effectiveness of this type of
combination in therapy and to prevent incidents
associated with cardiovascular diseases. Many stud-
ies of this type also included studies aiming at the
evaluation of the effectiveness of the concomitant
use of rosuvastatin, candesartan, and hydrochloroth-
iazide in patients with specific cardiovascular disor-
ders (1). The chemical structures of the tested sub-
stances are shown in Figure 1.
Candesartan (CAN) ñ 2-Ethoxy-1-{[2í-(1H-
tetrazol-5-yl)-4-biphenylyl]methyl}-1H-benzimida-
zole-7-carboxylic acid (Fig. 1A) is a selective AT1
receptor antagonist for angiotensin II. Blocking
these receptors leads to a lowering of blood pres-
sure, which is why these drugs are used to treat
hypertension.
Rosuvastatin (ROS) ñ (3R,5S,6E)-7-{4-(4-
Fluorophenyl)-6-isopropyl-2-[methyl (methylsul-
fonyl)amino]-5-pyrimidinyl}-3,5-dihydroxy-6-hep-
tenoic acid (Fig. 1B) belongs to the group of drugs
blocking the enzyme 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMG-CoA reductase),
which is crucial for cholesterol synthesis. As a
result, both LDL and total cholesterol are lowered.
In addition to lowering cholesterol, statins have
pleiotropic effects such as regulation of nitric oxide
synthesis leading to vasodilatation and show an
antioxidant effect.
Hydrochlorothiazide (HCT) ñ 6-chloro-1,1-
dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulfonamide (Fig. 1C) is a drug with diuretic and
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hypotensive effect from the thiazide group. It works
by inhibiting the reverse transport of sodium ions. In
this way, it increases the excretion of sodium and
water from the body. Its special significance results
from the long duration of action and is used in the
long-term treatment of hypertonia and chronic heart
failure. In addition, hydrochlorothiazide has been
used in the treatment of acute and chronic edema.
A number of methods have been described in
the literature that can be used to quantify the com-
pounds mentioned. The most commonly used meth-
ods are separation methods. The results of simulta-
neous determination of CAN and HCT using the
HPLC method are presented, among others, in
papers (2-5), by TLC method in papers (6-8).
In addition to separation methods, a spec-
trophotometric method using curves derived from
absorption spectra was successfully used to deter-
mine active substances in two-component mixtures
(10-12). ROS was also determined using separation
methods such as HPLC (13-15), TLC (16, 17), spec-
trophotometric method (18, 19), and electroanalyti-
cal methods(20-24).
The results of studies aiming at the evaluation
of the effectiveness of simultaneous use of the
above-mentioned drugs indicate a beneficial effect
of polytherapy (rosuvastatin 10 mg daily, candesar-
tan 16 mg daily, and hydrochlorothiazide 12.5 mg
daily), which is associated with a significantly lower
rate of cardiovascular events than in the placebo
group (25). Possible interactions between rosuvas-
tatin and candesartan and their tolerance by patients
were also investigated. The results confirmed that
the pharmacokinetic properties met the criteria for
bioequivalence. It was found that the FDC prepara-
tions were safe, well-tolerated and no significant
differences in the assessment of treatment safety
were observed (26). Therefore, the authors decided
to develop a method for the simultaneous determi-
nation of candesartan, hydrochlorothiazide, and
rosuvastatin as active ingredients of a potential FDC
(fixed-dose combination) preparations using thin-
layer chromatography with densitometric detection.
EXPERIMENTAL
Instruments and materials 
TLC system consists of Camag Linomat
autosampler (Sonnenmattstrasse 11, CH-4132
Muttenz, Switzerland), Camag microsyringe (100
µL), and Camag TLC scanner 35/N/30319 with
winCATS software. A short wavelength UV lamp
emitting at 254 nm and 366 nm was also used
(Desaga, Wiesloch, Germany). Aluminum-backed
TLC silica gel 60 F254 plates (20 × 20 cm) with 0.25
mm thickness were obtained from E. Merck,
Darmstadt, Germany. 
Chemicals 
Reference standards: candesartan (CAN) ñ 
2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phen-
yl]phenyl}methyl)-1H-1,3-benzodiazole-7-car-
boxylic acid, CAS Number: 145040-37-5,
hydrochlorothiazide (HCT) ñ 6-chloro-1,1-dioxo-
3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfon-
amide, CAS Number: 58-93-5, rosuvastatin (ROS) ñ
(3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(N-methyl-
methanesulfonamido)-6-(propan-2-yl)pyrimidin-5-
yl]-3,5 dihydroxyhept-6-enoic acid, CAS Number:
147098-20-2, were supplied by Sigma-Aldrich
(Germany). Hexane, ethyl acetate, methanol, 95.5%
acetic acid were purchased from Merck (Germany).
Figure 1. Chemical structure of candesartan (A), rosuvastatin (B), and hydrochlorothiazide(C).
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All reagents and solvents used were of analytical
reagent grade.
Pharmaceutical preparations
Two pharmaceutical preparations were used
for the determinations: Carzap®HCT 16 mg + 12.5 mg
manufactured by Zentiva, Prague, Czech
Republic, series No. 1608A045, one tablet con-
tains 16 mg of candesartan cilexetil and 12.5 mg
hydrochlorothiazide; Suvardio 10 mg manufac-
tured by Sandoz GmbH, Kundl, Austria, series No.
GB1246 one tablet contains 10 mg of rosuvastatin
calcium.
Standard solutions
The standard solutions were prepared by
weighing the appropriate mass of the standard sub-
stance on an analytical balance, transferring it quan-
titatively into a 10 mL volumetric flask, and making
it up to the given volume with methanol. By follow-
ing this procedure for all tested substances, clear
solutions were obtained at the following concentra-
tions: CAN: 0.960 mg/mL and 0.048 mg/mL, HCT:
0.760 mg/mL and 0.058 mg/mL, ROS: 0.640
mg/mL and 0.032 mg/mL.
Model mixture
10 tablets of Carzap®HCT and 10 tablets of
Suvardio were powdered. From the powdered tablet
mass, sample weights corresponding to the average
tablet weight of the tested preparations were made
and mixed. The model mixture was extracted with 
5 mL of methanol by placing the extract in an ultra-
sonic bath for 15 min. The solution was filtered
through EMD Millipore Syringe Filters 0.45 µm.
The mixture was diluted four times before the deter-
mination. The prepared solution containing CAN:
41.6%, HCT: 32.5%, ROS: 26.0% corresponded in
terms of composition and content to the mixture
used in polytherapy in clinical studies conducted
and described by Yusuf et al (25).
Mobile phase:
Hexane ñ ethyl acetate ñ methanol ñ water ñ
95.5% acetic acid (8.4 : 8 : 3 : 0.4 : 0.2 V/V)
Chromatographic conditions
In order to determine the separation conditions
of analyzed components, 2 µl of appropriate stan-
dard solutions of CAN at a concentration of 0.960
mg/mL, HCT at a concentration of 0.760 mg/mL,
ROS at a concentration of 0.640 mg/mL, and the
model mixture solution were applied in the form of
8 mm bands to the chromatographic plates measur-
ing 10 × 10 cm with silica gel G F254. Chromato-
grams were developed using a mobile phase com-
posed of: hexane ñ ethyl acetate ñ methanol ñ water
ñ 95.5% acetic acid (8.4 : 8 : 3 : 0.4 : 0.2 V/V). The
chromatogram was developed to a height of 95 mm
in a chromatographic chamber saturated with the
mobile phase for 15 min. After development, the
chromatograms were dried at room temperature and
subjected to visual analysis illuminating the chro-
matographic plate with monochromatic light at a
wavelength of l = 254 nm, and then the densitomet-
ric measurements were also performed.
METHOD VALIDATION
The method was validated according to the
ICH recommendations (27) and Polish Pharmaco-
poeia, XIth edition (28).
Specificity
Specificity was checked by comparing the
retention factor (RF) for the peaks of the standard
solutions and model mixture. The resolution of the
registered peaks was calculated (a ñ separation fac-
tor, Rs ñ resolution factor).
Accuracy
The accuracy of the method was determined by
providing the percentage of recovery (% R) of the
tested components. For this purpose, standard sub-
stances in amounts from 80% to 120% of the deter-
mined content were added to the model mixture. The
analysis was carried out before and after the addition
of standard substances. The recovery percentage was
calculated according to the formula: R = A/B × 100%,
where: A ñ the determined amount of tested sub-
stance, B ñ the known amount of tested substance.
Five repetitions were performed for each level.
Precision
Compliance of the determination results was
checked on standard solutions prepared by dissolv-
ing the ingredients in methanol, taking into account
the proportions in which they most often occur in
polytherapy. Five determinations were carried out at
three concentration levels: 50%, 100%, and 150% of
the determined content. 
Linearity
Linearity was defined as the relationship
between peak areas (p) and concentration (µg/spot),
using solutions at the following concentrations:
CAN 0.048 mg/spot, HCT 0.058 mg/spot, ROS
0.032 mg/spot. Two measurements were made for
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each component for concentrations respectively:
0.048, 0.240, 0.432, 0.672, 0.864, 1.056, 1.248,
1.440, 1.632, 1.824 mg/spot for CAN, from 0.058,
0.174, 0.290, 0.406, 0522, 0.638, 0.754, 0.870,
0.986, 1.000, 1.102 mg/spot for HCT and from
0.032, 0.160, 0.288, 0.448, 0.576, 0.704, 0.832,
0.960, 1.088, 1.216 mg/spot for ROS.
Limit of detection (LOD) and limit of quantifica-
tion (LOQ)
The limit of detection and quantification was
determined from the linearity in the concentration
ranges: from 0.048 to 0.0864 mg/spot for CAN,
from 0.058 to 0.522 mg/spot for HCT and from 0.032
to 0.832 mg/spot for ROS. The following formulas
Figure 2. Spectra of CAN, HCT, and ROS recorded directly from a chromatogram.
Figure 3. Two-dimentional TLC densitogram of CAN (c = 3.2 mg/mL), HCT (c = 2.5 mg/mL) and ROS (c = 2.0 mg/mL).
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Table 1. Validation of the developed method with the statistical evaluation.
CAN HCT ROS
RF ~ 0.66 ~ 0.41 ~ 0.53
Linearity range (µg/spot) 0.048 - 1.824 0.058 - 1.102 0.032 - 1.216
LOD (µg/spot) 0.056 0.043 0.049
a 5828.7 6992.3 5051.0
Sy 98.6 91.3 75.8





SD 0.0094 0.0050 0.0048





SD 0.0088 0.0105 0.0058





SD 0.0270 0.0033 0.0067





SD 0.367 1.226 0.808





SD 1.280 1.798 0.559





SD 0.723 0.747 0.706
RSD 0.7 0.8 0.7
Rs HCT : ROS ROS : CAN
1.80 2.50
α HCT : ROS ROS : CAN
1.62 1.82
RF - retention factor,  - mean value, SD - standard deviation, RSD - relative standard deviation, Rs - resolution
factor,   - separation factor.
were used in the calculations: LOD = 3.3 × Sy/A,
LOQ = 10 × Sy/A, in which: Sy ñ standard error of
the estimate, a ñ the slope of the straight line.
Robustness
The robustness of the method was verified by
analyzing the influence of slight changes in the sys-
tem on the obtained results. The following parame-
ters were changed: chromatographic chamber satura-
tion time ± 10 min, the volume of the mobile phase
± 5%, type of the stationary phase (HPTLC 60F254),
type of the chromatographic chamber used. None of
these changes influenced the obtained results, which
may prove that the method is resistant.
Determination of components in the model mix-
ture
The usefulness of the method was assessed by
determining the content of tested substances in mix-
tures resulting from the appropriate solutions pre-
pared from pharmaceutical preparations. 2 µL of
standard solutions and the model mixture were
applied to TLC plates. Developed and dried chro-
matograms were subjected to densitometric meas-
urements at the previously given wavelengths.
Identification of the determined components was
made by comparing the values of RF coefficients and
absorption spectra for the tested model mixtures and
standard solutions. To calculate the content of active
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substances in the model mixture, the peak areas reg-
istered for the tested solutions and the corresponding
standard solutions were compared.
RESULTS AND DISCUSSION
The development of the concept of polytablets
and research on their application in the therapy and
prevention of diseases related to the cardiovascular
system, along with the development of technologi-
cal methods to obtain an effective and safe form of
the drug, leads to the need to search for new, simple,
cheap, and effective methods of analysis of multi-
component drugs.
In accordance with the assumption adopted for
the purpose of the work, a new chromatographic and
densitometric procedure was developed, allowing
for the simultaneous identification and quantifica-
tion of active substances in a potential ternary poly-
tablet composed of CAN, HCT, and ROS. After
analyzing the absorption spectra of the tested drugs
registered directly from the chromatograms in the
range from 200 to 400 nm (Fig. 2), it was found that
due to the overlap of absorption maxima for indi-
vidual components, it is difficult to use the spec-
trophotometric method to determine these sub-
stances in a mixture (12). These interferences mean
that the determination of the analytical wavelength
for individual components in their mixture does not
guarantee satisfactory quantitative results using
spectrophotometric or spectrofluorimetric methods.
The selection of a suitable mobile phase was
preceded by a literature review and was based on a
series of tests that took into account the different
qualitative and quantitative composition of solvents.
The suitability of the chloroform: methanol: 95.5%
acetic acid mixture (9 : 2 : 0.1 V/V) was checked.
The use of this phase gave poor resolution and an
asymmetrical peak of CAN. In the chloroform: ethyl
acetate: 95.5% acetic acid : water (4 : 4 : 4 : 1 V/V)
mixture, proper separation of HCT and ROS peaks
was not achieved, RF values were very close to each
other, which did not guarantee adequate accuracy
and precision of determinations. Only the use of a
mixture composed of hexane : ethyl acetate :
methanol : water : 95.5% acetic acid (8.4 : 8 : 3 : 0.4
: 0.2 V/V) and the use of TLC plates coated with sil-
ica gel 60 with the fluorescent agent F254 allowed to
obtain well-shaped, separated and symmetrical
peaks for all tested substances. Only peaks from the
analyzed components appear on the recorded densi-
tograms. RF values were comparable and were
respectively 0.66 ± 0.013 for CAN, 0.41 ± 0.009 for
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basis for using the developed procedure in the quan-
titative analysis. It can therefore be assumed that the
method is specific for analyte components, which
allows obtaining reliable results (Fig. 3).
The developed method has been fully validated
in accordance with the guidelines of the
International Conference on Harmonization. In the
validation process, linearity, accuracy, precision, the
limit of detection LOD, and limit of quantification
LOQ were determined. The method is characterized
by a high sensitivity; LOD was 0.056 mg/spot for
CAN, 0.043 mg/spot for HCT and 0.049 mg/spot for
ROS; LOQ was: 0.169 mg/spot, 0.130 mg/spot and
0.150 mg/spot, respectively. Recovery of the deter-
mined components was in the range from 96.80% to
101.75%. The results of the determination of indi-
vidual components are characterized by high preci-
sion, RSD was in a narrow range from 0.43% to
2.12%. The determined validation parameters are
presented in Table 1. 
The linearity of the method was checked in a
wide concentration range: from 0.048 to 1.824
mg/spot for CAN, from 0.058 to 1.102 mg/spot for
HCT and from 0.032 to 1.216 mg/ spot for ROS. 
The efficiency of the estimation of calibration
models was checked by conducting appropriate sta-
tistical tests. Based on Mandelís test results (p <
0.05 for all tested substances) a quadratic fit was
selected. The normal distribution of residuals was
confirmed in all cases by the Shapiro-Wilk test. The
Durbin-Watson test results indicate no significant
autocorrelation of random components only in the
case of ROS. The Lagrange test was performed for
HCT and CAN, which showed no significant auto-
correlation. The Bartlett test confirmed the homo-
geneity of the variance of random components in the
proposed models (p > 0.05). The results of statistical
tests and equations are presented in Table 2.
The proposed method was successfully used
for the analysis of Carzap®HCT and Suvardio tablet
extract solution ñ model mixture (Table 3). The
chromatograms obtained during the analysis, on
which no additional peaks from the auxiliary com-
ponents of the tested drug form were observed and
recovery values indicate that the excipients have no
effect on the determination results. This allows us to
state that with minimal effort and the elimination of
complicated activities related to the appropriate
sample preparation, results with a satisfactory level
of precision and accuracy have been achieved.
CONCLUSIONS
This study presents a new method for the
simultaneous determination of candesartan,
hydrochlorothiazide, and rosuvastatin in a model
mixture of a potential ternary pharmaceutical prepa-
ration using TLC ñ densitometric method. The
developed procedure has been validated in accor-
dance with the ICH requirements for chromato-
graphic methods. The TLC method is fast and
requires no complicated pre-treatment or tedious
extraction procedure, and the obtained results are
characterized by high accuracy and precision. The
choice of the components of the model mixture was
not accidental because in hypertension polytherapy
you can find more and more often research on the
effectiveness of using various combinations of sub-
stances from the group of angiotensin II receptor
blockers, diuretics, and HMG-CoA reductase block-
ers. Due to such a direction in therapy, the pharma-
ceutical industry is introducing new complex prepa-
rations to the market, which in clinical trials gave
satisfactory results and underwent the registration
procedure. However, the goal of analysts is to devel-
op new, simple, cheap, and easily available methods
that could be used for routine analysis of tested
drugs in quality control laboratories. 
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Table 3. Determination results of active substances in a studied model mixture (n = 5).
Model CAN HCT ROS








Determined content SD = 0.0161 SD = 0.0040 SD = 0.0067
RSD = 2.0% RSD = 0.6% RSD = 1.3%
Stated content 0.800 0.625 0.500
X
ñ
- mean value, SD - standard deviation, RSD - relative standard deviation.
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